U.S., May 29 -- ClinicalTrials.gov registry received information related to the study (NCT07612345) titled 'High-Dose Vitamin C in G6PDA and Pyruvate Kinase Deficiency: A Safety Study' on May 19.
Brief Summary: This study is testing whether high-dose Vitamin C is safe and well-tolerated in patients with two inherited red blood cell disorders - Pyruvate Kinase Deficiency (PKD) and Class A Glucose-6-Phosphate Dehydrogenase Deficiency (G6PDA). Both conditions cause red blood cells to break down too quickly, leading to anemia and related complications.
Our earlier research showed that a single oral dose of Vitamin C (250 mg, 500 mg, or 750 mg) reduced red blood cell breakdown by approximately 50% within one hour. This study builds on those fi...